Business Description
ARS Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US82835W1080
Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 833.43 | |||||
| Equity-to-Asset | 0.99 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 192.55 | |||||
| Beneish M-Score | 7.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -421.5 | |||||
| 3-Year EPS without NRI Growth Rate | -272.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.62 | |||||
| 9-Day RSI | 39.57 | |||||
| 14-Day RSI | 42.61 | |||||
| 6-1 Month Momentum % | 184.09 | |||||
| 12-1 Month Momentum % | 54.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 96.92 | |||||
| Quick Ratio | 96.92 | |||||
| Cash Ratio | 95.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 0.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -225066.67 | |||||
| Net Margin % | -181216.67 | |||||
| FCF Margin % | -198136.67 | |||||
| ROE % | -21.73 | |||||
| ROA % | -21.02 | |||||
| ROIC % | -1348.3 | |||||
| ROC (Joel Greenblatt) % | -6950.79 | |||||
| ROCE % | -26.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.49 | |||||
| Price-to-Tangible-Book | 3.49 | |||||
| EV-to-EBIT | -8.18 | |||||
| EV-to-EBITDA | -8.19 | |||||
| EV-to-Revenue | 18420.4 | |||||
| EV-to-FCF | -9.3 | |||||
| Price-to-Net-Current-Asset-Value | 3.51 | |||||
| Price-to-Net-Cash | 3.57 | |||||
| Earnings Yield (Greenblatt) % | -12.22 | |||||
| FCF Yield % | -7.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SPRY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ARS Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.03 | ||
| EPS (TTM) ($) | -0.57 | ||
| Beta | 0 | ||
| Volatility % | 75.33 | ||
| 14-Day RSI | 42.61 | ||
| 14-Day ATR ($) | 0.506547 | ||
| 20-Day SMA ($) | 9.007 | ||
| 12-1 Month Momentum % | 54.8 | ||
| 52-Week Range ($) | 2.55 - 11.27 | ||
| Shares Outstanding (Mil) | 96.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ARS Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ARS Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ARS Pharmaceuticals Inc Frequently Asked Questions
What is ARS Pharmaceuticals Inc(SPRY)'s stock price today?
The current price of SPRY is $8.35. The 52 week high of SPRY is $11.27 and 52 week low is $2.55.
When is next earnings date of ARS Pharmaceuticals Inc(SPRY)?
The next earnings date of ARS Pharmaceuticals Inc(SPRY) is 2024-05-15 Est..
Does ARS Pharmaceuticals Inc(SPRY) pay dividends? If so, how much?
ARS Pharmaceuticals Inc(SPRY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers